Metabolomics markers in Neurology: current knowledge and

future perspectives for therapeutic targeting. by Bonomo, Roberta et al.
For Peer Review Only
Metabolomics markers in Neurology: current knowledge and 
future perspectives for therapeutic targeting. 
Journal: Expert Review of Neurotherapeutics
Manuscript ID ERN-2020--0055.R1
Manuscript Type: Review (invited)
Keywords: metabolomics, biochemical markers, metabolites, neurology, drug targets
 
URL: https://mc.manuscriptcentral.com/ern   Email: IERN-peerreview@journals.tandf.co.uk
Expert Review of Neurotherapeutics
For Peer Review Only
1
1 Metabolomics markers in Neurology: current knowledge and future perspectives 
2 for therapeutic targeting.
3
4 Abstract
5
6 Introduction: Metabolomics is an emerging approach providing new insights into the 
7 metabolic changes and underlying mechanisms involved in the pathogenesis of 
8 neurological disorders. 
9 Areas covered: Here, we present an overview of the current knowledge of metabolic 
10 profiling (metabolomics) to provide critical insight on the role of biochemical markers 
11 and metabolic alterations in neurological diseases.
12 Expert opinion: Elucidation of characteristic metabolic alterations in neurological 
13 disorders is crucial for a better understanding of their pathogenesis, and for identifying 
14 potential biomarkers and drug targets. Nevertheless, discrepancies in diagnostic 
15 criteria, sample handling protocols, and analytical methods still affect the 
16 generalizability of current study results.
17
18 Keywords: metabolomics; biochemical markers; metabolites; neurology; drug targets.
19 Highlights:
20  Metabolomics is an emerging approach providing new insights into individual 
21 metabolic profile.
22  The investigation of characteristic metabolic alterations in neurological disorders is 
23 crucial for a better understanding of their pathogenesis.
24  Metabolomics markers hold the potential of improving diagnosis, follow-up of 
25 patients, and clinical trial outcomes.
26  Discrepancies in the phenotyping/classification of the neurological diseases and 
27 their subtypes, the mixed cohorts of patients and uncontrolled sampling conditions, 
28 have, to date, prevented identification of clear metabolic profiles and pathways.
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29 1. Introduction
30
31 The development of innovative tools, screening approaches, and imaging techniques 
32 has indeed improved the study of the biochemical or cellular mechanisms and their 
33 homeostasis in the central and peripheral nervous system. Genomics and proteomics 
34 have been widely explored in the last decades. Nevertheless, variations in 
35 transcriptional/translational processes determine that gene transcript levels do not 
36 always correlate with protein expression [1]. As a result, quantification of proteins 
37 might not always capture post-translational modification effects on protein synthesis 
38 [1]. More recently metabolic markers have offered promise to better understand and 
39 predict the development of neurological disorders [2].
40 Compared to genes and proteins, plasma metabolic profiling (metabolomics) presents 
41 the advantage of better reflecting the resulting interplay between environmental and 
42 genetic factors, and holds the potential of improving diagnosis, follow-up of patients, 
43 and clinical trial outcomes. In particular, metabolomics aims at identifying metabolites 
44 related to pathways implicated in the development and progression of the disorder, thus 
45 improving the knowledge about the disease pathogenesis [2]. 
46
47 1.1 Metabolic pathways of the nervous system
48 Brain energy-demands account for about 25% of total glucose source in our body, 
49 despite the lack of an energy-generating storage such as glycogen or fat. Neurons 
50 mostly rely on glucose supply for adenosine triphosphate (ATP) production, and 
51 accordingly mitochondria dysfunction and bioenergy deficits have long been proposed 
52 as the mechanism underlying chronic neuronal damage. Reduced energy metabolism 
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53 has been well documented through the positron emission tomography (PET) scan 
54 analysis in neurodegenerative disorders [3-7]. 
55 Some authors proposed that astroglial and neuronal mitochondria oxidize not only 
56 glucose but a combination of substrates, including 𝛽-oxidation of fatty acids, pyruvate, 
57 lactate, and neuromediators such as glutamate and GABA [8,9]. Indeed, lipids play a 
58 critical role in central nervous system homeostasis, including formation of lipid rafts, 
59 maintenance of cell membrane structure, and involvement in signal transduction [10-
60 12]. It has been estimated that about 20% of the total energy requirement of the brain 
61 is provided by the oxidation of fatty acids [13]. The supplement of amino acids is less 
62 significant and, during gluconeogenesis and neuronal activity, the pool of amino acids 
63 must be constantly replaced by transamination of 𝛼-ketoglutarate, pyruvate, or 
64 proteolysis of proteins. 
65 The neuronal microenvironment is regulated by a well-organized neurovascular system 
66 which filters the exchange of biomolecules and xenobiotics through the blood–
67 cerebrospinal fluid barrier. The model of the third circulation between the 
68 cerebrospinal and interstitial fluids (CSF and ISF) was first proposed in 1900 by Harvey 
69 Williams Cushing and Louis Weed [14-16]. Beyond the blood-brain barrier (BBB), a 
70 combination of intracellular and extracellular enzymes also contributes to the molecular 
71 trafficking with a metabolic barrier, which can metabolize and inactivate many 
72 neuroactive and toxic compounds [17,18].
73 The peripheral nervous systems (PNS), compared to the central nervous system (CNS), 
74 is more exposed to toxic agents due to the presence of a less effective blood–nervous 
75 system barrier. Differently from the brain, peripheral nerves have a lower energy 
76 demand both at rest or under stimulation. Nerve axons and Schwann cells use a 
77 composite pattern of substrates for energy provision. They derive the major fraction of 
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78 their composite energy requirements from glucose [19]. Ketone bodies can also 
79 contribute to part of the energy requirements [19]. Most of the glucose in peripheral 
80 nerves is preferentially taken up by Schwann cells [20], which hold the highest 
81 concentration of aldose reductase [21,22]. The polyol pathway plays a central role in 
82 peripheral nerve metabolism and survival in normoglycemic conditions [23]. Neurons 
83 in the dorsal root ganglia (DRG) also play a critical role in the metabolic support of the 
84 nerve, and apparently exhibit a greater capability of responding to metabolic insult 
85 through continuous synthesis and refolding of proteins than the axonal compartment 
86 [24]. 
87 As a result of large energy stores and minor oxygen requirements, nerve metabolism 
88 can be adequately supported by anaerobically generated high energy phosphates. It has 
89 been previously demonstrated by Fink and colleagues that peripheral nerves can 
90 conduct impulses for a prolonged period of time even with a limited source of glucose 
91 [25]. It has been shown that nerves are able to adapt their oxygen consumption in 
92 conditions of reduced supply such as hypoxia [26] or aging [27]. Investigations have 
93 also outlined the importance of vesicular glycolysis as means of on-board energy for 
94 fast axonal transport [28]. 
95
96 1.2 Metabolomics daily-cycle 
97 “Circadian metabolism” refers to the circadian (24 h) control of metabolism to optimize 
98 energy storage and utilisation across the day and night, by aligning the timing of 
99 sequentially dependent processes. In addition, these daily oscillating biochemical 
100 changes in human systemic and tissue-specific metabolic pathways are associated with 
101 the sleep/wake, feeding/fasting and light/dark state. Local metabolism is usually 
102 synchronized and driven by a central clock, located in the suprachiasmatic nuclei (SCN) 
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103 in the light-responsive region of the anterior hypothalamus. The rhythmic production 
104 of the hormones, melatonin and cortisol, are directly regulated by the SCN, therefore 
105 representing reliable markers of the phase of the central SCN clock [29]. In addition to 
106 these circadian endocrine rhythms, the circadian signal is also transmitted via 
107 sympathetic and parasympathetic neural circuits to the periphery. All mammalian 
108 tissues including the metabolically active liver, skeletal muscle and adipose tissue, 
109 express independent clocks. These local peripheral clocks (but not the clock in the 
110 SCN) entrain to meal timing [30,31] and are all well placed to regulate metabolic 
111 processing. Interestingly, glucocorticoids can also influence peripheral rhythmicity 
112 independently from central SCN control [32]. It has also been demonstrated that 
113 circadian clocks in liver, adipose tissue, muscle, and kidney are all highly based on 
114 nutrients supply and food intake [33-35]. There has been clear evidence in humans that 
115 most of detected metabolites show 24 h diurnal rhythmicity when the sleep/wake and 
116 feeding patterns are regular [36,37]. In these studies, most of the metabolite rhythms 
117 persisted during acute total sleep deprivation [36,37]. Endogenous circadian rhythms in 
118 metabolites/lipids have also been reported in humans when controlling/minimizing the 
119 confounding effects of activity, light, temperature, sleep, and food intake [38-40].
120 Therefore, when considering metabolite data, it is crucial to control the sampling time 
121 (time stamp) for an accurate interpretation. Accordingly, sequential sampling at regular 
122 time intervals across the 24 h day might more realistically reflect systemic metabolic 
123 pathways and dynamic tissue-related activity. 
124
125 1.3 Metabolomics approaches
126 The human metabolome consists of thousands of metabolites, including water-soluble 
127 and lipid-soluble molecules [41-43]. Indeed, the multiple chemical properties and 
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128 varying concentrations do not facilitate metabolite investigation. The application of 
129 multiple metabolomics tools has helped to extend metabolite coverage [44].
130 The classification of different metabolites and altered metabolic pathways has so far 
131 been based on either targeted [43] or untargeted methods [45]. The former approach 
132 mainly focuses on identifying and quantifying predefined metabolites/lipids. The latter 
133 by contrast addresses a more comprehensive analysis of metabolites/lipids, albeit less 
134 specific. Indeed, the combination of both targeted and untargeted analyses provide 
135 better repeatability and a more extensive investigation range [46]. 
136 Mass spectrometry (MS) and nuclear magnetic resonance (NMR) are the most widely 
137 used platforms. The combination of MS and chromatography separation technologies 
138 can reduce the complexity of biological samples, helping to differentiate isobaric 
139 compounds and reduce ionization suppression [47]. The main separation methods are 
140 based on gas chromatography (GC), liquid chromatography (LC) and capillary 
141 electrophoresis (CE). The development of gas chromatography-mass spectrometry 
142 (GC-MS) related metabolomics involves the detection of new metabolites with 
143 decreased false positive and false negative rates through rapid separation and automatic 
144 data processing. Gas chromatography consists of a two-step approach (derivatization 
145 and chromatographic separation) appropriate for analyzing volatile and semi-volatile 
146 metabolites, and it currently represents the most popular method. The accuracy of 
147 metabolite identification has been increased through a retention index (RI), and specific 
148 algorithms and software to facilitate metabolite investigation [48,49] and data 
149 processing [50,51]. GC-MS has demonstrated advantages in identifying metabolites 
150 derived from the tricarboxylic acid (TCA) cycle, glycolysis, fatty acid and amino acid 
151 metabolic pathways. GC-MS metabolomics approaches have been used successfully to 
152 study cancer markers [52-54]. By contrast to GC-MS, LC-MS also covers non-volatile 
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153 metabolites [55]. Ultra-high-performance LC (UHPLC) provides an accurate 
154 separation of polar metabolites [56], whereas reversed-phase liquid chromatography 
155 (RPLC) is ideal for hydrophobic metabolite detection. RPLC-MS related metabolomics 
156 has been widely applied for detecting biomarkers [57,58], including fatty acids and 
157 carnitines [59], and understanding disease mechanisms [60]. Capillary electrophoresis 
158 (CE)-MS is indicated for central carbon metabolites, nucleotides, co-enzymes, sugar 
159 nucleotides and amino acids [61,62], and it has been used inter alia in studies 
160 concerning diabetes [63] and cancers [64]. 
161 Direct infusion mass spectrometry (DIMS) is currently the main stream lipidomics 
162 method. NMR can provide structure information for metabolite identification and is 
163 increasingly used in metabolomics studies. Two-dimensional (2D) NMR provides 
164 increased resolution, albeit lower sensitivity [65,66]. Stable isotope tracer-based 
165 metabolomics (SITBM) and fluxomics approaches are instead focused on the 
166 calculation of the in vivo rate of metabolic fluxes in pathways [67]. A number of 
167 software packages and complex algorithms have been developed for precise 
168 quantification of metabolite flux rates [68,69]. Fluxomics has also recently been applied 
169 to investigate cancer [70] and the cell cycle [71].
170 Over recent years, many metabolomics studies have been developed for answering 
171 clinical scientific issues and understanding disease pathogenesis [72]. Clinical demands 
172 have promoted the development of quick, accurate, sensitive and relatively low-cost 
173 technologies. Analytical methods used to conduct metabolomics studies include NMR, 
174 GC-MS and LC-MS [73,74]. Indeed, MS and NMR provide complementary data and 
175 both analytical platforms are often required for a comprehensive characterization of 
176 compounds [74]. For instance, NMR can differentiate isobaric compounds and 
177 positional isomers, while MS can identify certain functional groups such as sulfate and 
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178 nitro groups, which are NMR silent [74]. For detailed descriptions of these analytical 
179 methods, we suggest a recent review of Gathungu and colleagues [74]. 
180 Quality and timing of clinical samples are also crucial [75,76]. Ideally fasting samples 
181 should be collected. Food composition will affect the metabolic profile thus knowledge 
182 of the meal content and timing prior to sampling will help to interpret the metabolomics 
183 results. In controlled metabolomics studies, meal timing and content should be 
184 standardized [36,37]. Preanalytical variables, including blood collection tubes, 
185 hemolysis, temperature and time before further processing, and number of freeze/thaws 
186 can significantly impact the metabolic profile [75,76]. Analyses on mealtime, temporal, 
187 and daily influence on metabolites revealed higher metabolome variability after the 
188 morning compared to the evening meal, with more pronounced variability in urine than 
189 blood [77]. Specifically, glucose and other sugars as well as phospholipids changed in 
190 the post-prandial state as well as citric acid compared to other metabolites. Accordingly, 
191 it would be relevant to standardize meals when studying TCA cycle involved diseases. 
192
193 1.4 Metabolomics and aging
194 A better definition of the progressive change of the metabolome profile with aging 
195 might further disclose the mechanisms through which age influences disease 
196 development and progression from its early stages. Metabolites vary with age in 
197 different species, including mice [78-80]. Metabolomics studies on aged mouse brains 
198 revealed significant variations in amino acid and nucleotide metabolism [81]. Indeed, 
199 the role of oxidative stress in aging has been well recognized [82,83]. Oxidative stress 
200 can result from the disproportionate bioavailability of reactive species responsible for 
201 functional alterations related to aging. In particular, variations in the plasma levels of 
202 metabolites from beta-oxidation of fatty acids, glycophospholipid and sphingolipid 
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203 metabolism, may be strongly associated with physiological aging [84]. Relevant 
204 changes in the constituents of cell membranes, including phospholipids (PLs) and 
205 sphingomyelins (SMs), acylcarnitines (ACs), and some amino acids, such as histidine, 
206 have been described with age progression [85]. 
207 Dysregulation of the immune system has also been theorized to be involved in the aging 
208 process [86]. Investigations on the murine transcriptome showed a negative correlation 
209 between systemic lipid metabolism and the immune response during aging [87]. 
210 Therefore, dysregulation of both the alteration in redox homeostasis and the immune 
211 system apparently contribute to ageing [86]. For example, peroxidation of cell 
212 membrane lipids in the eld rly population might affect the capability of immune cells 
213 to react to mitogens [88,89]. 
214 A number of studies have attempted to investigate the relationship between age, sex 
215 and the metabolite profile [85,90-95]. Darst and colleagues performed the first 
216 longitudinal analysis to capture age-related phenomena in the human metabolome [96]. 
217 The authors found relevant differences for both age and sex in levels of plasma lipid 
218 steroids, including androgens, progestins, and pregnenolones. Sphingolipids and fatty 
219 acid lipids were also significantly associated with increased age. Most of the age-related 
220 amino acids, namely glutamine and tyrosine, were augmented, conversely, histidine, 
221 threonine, tryptophan, leucine, and serine decreased. These results provided strong 
222 evidence that most plasma metabolites are highly influenced by aging with a greater 
223 effect on metabolites in women than men. Specifically, in line with previous studies, 
224 phosphatidylcholines and sphingolipids levels tended to be higher in women than men 
225 [90,95-97], while serum ACs were lower in women [90,96]. Unfortunately, the 
226 sampling protocols and collection time-points were not specified in these studies. The 
227 KORA F4 study also reported an increase in serum sphingolipids according to age in 
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228 women, and increased ACs in both women and men [95]. Indeed, dramatic hormone 
229 changes and loss of ovarian function would influence metabolite values in women, 
230 whereas men experience a more progressive decline of hormones and fertility [98]. As 
231 a result, post-menopausal women exhibit an increase in SMs, fatty acids, ACs and 
232 LysoPCs [99,100]. Despite this sexual dimorphism in the plasma metabolomics profile, 
233 Jové and colleagues tried to identify novel metabolites presenting the same trend of 
234 variation in both genders as biomarkers of aging [101]. The authors demonstrated a 
235 decrease in specific lipids, namely vitamin D2-related compound, phosphoserine 
236 (40:5), monoacylglyceride (22:1), diacylglyceride (33:2), and resolvin D6, emerging 
237 with the aging process, ind pendently of gender. Some studies also attempted to define 
238 the relationship between longevity and lipid profiles. In particular, Jovè and colleagues 
239 investigated the lipid pattern of centenarian subjects [102]. The authors reported a 
240 significantly higher average chain length and saturated fatty acid content, and a lower 
241 content of polyunsaturated fatty acids in centenarians compared to non-centenarians. 
242 Another study on human longevity reported a significant decrease in both alkyl and 
243 alkenyl lipids, with a reduced content in plasmalogens for alkenyl lipids, in centenarians 
244 compared to non-centenarians [103]. This specific compositional lipid pattern implies 
245 that the density of double bonds and susceptibility to peroxidation, which increases in 
246 relation to the number of double bonds per fatty acid [104], were significantly lower in 
247 centenarians compared to non-centenarians, indicating that ether lipids from 
248 centenarians are more resistant to lipid peroxidation.
249
250 2. Metabolomics in neurodegenerative disorders
251 The classification of neurodegenerative disorders has yet to be defined in terms of its 
252 mechanistic progression and pattern of deterioration [105]. Considering the significant 
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253 impact at the social and economic level, the identification of markers reflecting 
254 neurological disease development or worsening might be fundamental for therapeutic 
255 intervention and clinical management.
256 2.1 Amyotrophic lateral sclerosis
257 There have been a number studies investigating metabolomics markers in amyotrophic 
258 lateral sclerosis (ALS). Bjornevik and colleagues in a recent study explored plasma 
259 metabolites suggestive of metabolic dysregulation years before the onset of the disease 
260 [106]. Results suggested that alterations in lipid metabolism are likely to be related to 
261 the earliest phases of the disorder [106]. This finding supports previous animal models 
262 showing a preference for lipids as a source of energy during the asymptomatic stage 
263 [107]. Others have observed an increase in the levels of ketone bodies, derived from 
264 the utilization of fatty acids, in patients affected by symptomatic ALS [108]. The 
265 restricted use of lipids as the fuel source in motoneurons is associated with increased 
266 oxidative stress [109], which determines neuroinflammation, mitochondrial 
267 dysfunction, and excitotoxicity [110], eventually resulting in cellular death. Cacabelos 
268 and colleagues investigated the chronic excitotoxicity changes in lipid composition in 
269 spinal cord samples from ALS patients [111]. The authors reported an increase in 
270 docosahexaenoic acid (DHA), a key lipid in nervous system homeostasis, with both 
271 enhanced concentrations of neuroprotective docosahexaenoic acid-derived resolvin D, 
272 and higher lipid peroxidation-derived molecules. This overload, involving the 
273 expression of DHA synthetic enzymes, could later on exacerbate cell stress by 
274 contributing to TDP-43 aggregation and motoneurons loss. Others investigated 
275 potential metabolic signatures in ALS through an untargeted metabolomics approach 
276 comparing cerebrospinal fluid (CSF) from ALS patients to controls [112]. Metabolome 
277 analysis correctly predicted the diagnosis of ALS in more than 80% of cases. In 
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278 particular, concentrations of glutamate and ascorbate were found to be significantly 
279 higher in ALS patients than controls (p=0.0002). Investigations of the CSF metabolome 
280 in ALS patients with different mutations in the Cu/Zn-superoxide dismutase (SOD1) 
281 gene further disclosed a distinctively different metabolomics signature in patients 
282 carrying a D90A SOD1 mutation compared to other groups [113]. In particular, 
283 arginine, lysine, ornithine, serine, threonine and pyroglutamic acid were all found to be 
284 reduced in patients carrying a D90A SOD1 mutation, thus contributing most to the CSF 
285 signature. In this regard, the use of metabolomics as a means to understand pathway 
286 information in genome-wide association studies could be of great interest for 
287 interpreting the effects of different mutations in ALS subtypes.
288 Some studies have also revealed an increase in plasma cysteine [114,115], which plays 
289 an antioxidant role, and a decrease in methionine [116], an intermediate in the 
290 biosynthesis of cysteine, suggesting a compensatory mechanism for the oxidative stress 
291 state.
292 2.2 Alzheimer’s disease
293 There has also been great advance in defining metabolomics changes associated with 
294 the central pathology of Alzheimer’s disease (AD). In AD, metabolomics investigations 
295 have demonstrated a reduction in ethanolamine plasmalogens (PlsEtn) in both brain 
296 [117-119] and plasma [120,121]. Plasmalogens are essential endogenous antioxidants, 
297 which protect other PL, lipid and lipoprotein particles from oxidative stress [122]. As 
298 for ALS, analysis of CSF and blood of patients with AD revealed a decrease of several 
299 lipid classes, including PL, phosphatidylcholines (PCs), phosphatidylinositols, 
300 sphingolipids, lysophospholipids, SMs, and sterols [10,12,123,124], supporting the 
301 hypothesis of a metabolic imbalance towards oxidative stress in AD. Nevertheless, the 
302 time course of these metabolite changes in relation to AD progression remains to be 
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303 elucidated. Han and colleagues described a significant depletion in sphingolipids, 
304 particularly those containing long aliphatic chains such as 22 and 24 carbon atoms, and 
305 decreased levels of ceramides in early AD patients compared to controls [125]. Others 
306 have highlighted the potential link between altered plasma ceramide levels and 
307 hippocampal volume loss in mild cognitive impairment (MCI), supporting the 
308 hypothesis that alterations in ceramide metabolism may be related to early 
309 neuropathological changes [126]. A very recent study from Bernath and colleagues has 
310 investigated the association of serum triglycerides in AD with neuroimaging and CSF 
311 biomarkers [127]. Results suggest that long-chain, polyunsaturated fatty acid-
312 containing triglycerides were significantly associated with MCI and AD, as well as with 
313 hippocampal volume and entorhinal cortical thickness. Furthermore, in those 
314 participants carrying the APOE ε4 allele these principal components were significantly 
315 associated with CSF β-amyloid1-42 values and entorhinal cortical thickness. 
316 Concerning amino acid metabolism in AD patients, a reduction of branched-chain 
317 amino acids (BCAAs) [128,129], creatinine [129], and taurine [130] has been observed; 
318 while higher glutamate [130] and glutamine [131] levels were found. Interestingly, a 
319 metabolomics study on the entorhinal cortex has shown changes in the expression levels 
320 of deoxyguanosine, xanthosine and guanine in early stages of the disorder, followed by 
321 modifications in dGMP and glycine in advanced stages [132]. The observed regional 
322 differences in purine metabolism in AD cortex highlight the need for considering 
323 regional specificities as markers of regional vulnerability.
324 Niedzwiecki and collaborators have recently conducted a study aimed at identifying 
325 metabolic AD markers in CSF and blood samples [133]. This study has the advantage 
326 of comparing systemic metabolites (blood analysis) with products derived from the 
327 CNS (CSF analysis), thus overcoming the difficulty in interpreting previous results due 
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328 to the use of different substrates [133]. The study involved two independent populations 
329 of AD patients who underwent CSF and blood collection. The results confirmed 
330 previous findings reporting elevated plasma glutamine in AD [134-139]. These 
331 glutamine levels were positively correlated with APOE-e4 genotype, and CSF t-Tau 
332 and p-Tau181 levels [133]. These authors thus suggested the possibility of using 
333 glutamine as a biomarker to identify AD patients susceptible to excitotoxicity. The 
334 study also found reduced levels of piperine, which was negatively associated with CSF 
335 p-Tau181. Reduction of piperine could be ascribed to its antioxidant [140], anti-
336 inflammatory [141], and anti-secretase [142] activities. The importance of 
337 Niedzwiecki’s study [133] lies in the identification of metabolites reproducibility 
338 altered in AD dementia. Validation of sensitive and comprehensive lipid biochemistry 
339 platforms might further disclose the ability to analyze the different pathways that may 
340 be involved in AD in relation to clinical phenotype and genotype.
341 2.3 Multiple Sclerosis
342 Metabolomics approach has also been used to study Multiple Sclerosis (MS). Stoessel 
343 and colleagues reported a decrease in PCs and lysophosphatidylcholines (LysoPCs) 
344 during the primary progressive form of MS [143], whereas others observed a change in 
345 the ratio of LysoPC/PC lipid profile in the plasma of patients with clinically diagnosed 
346 relapsing–remitting MS [144] and in the CSF of patients with AD [145]. PCs are 
347 important for the structural supports of cells, and for anti-inflammatory signaling [146]. 
348 Altered metabolism of sphingolipids has also been described in both MS [147] and AD 
349 [127]. Sphingolipids are also involved in both the structural components of cell 
350 membranes and sustaining cellular signaling [148]. Myelin damage determines the 
351 release of its structural components in CSF and blood stream, which can be considered 
352 as potential biomarkers of the disease [149,150]. In MS, an increase in taurine 
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353 concentration in the spinal cord and CSF has also been reported [151,152], possibly 
354 related to the immunomodulatory and neuroprotective reaction against the progressive 
355 nerve injury. Lipidomics assessment of CSF has demonstrated that MS patients present 
356 a different lipid profile at the time of diagnosis compared with non-MS subjects [153]. 
357 Specifically, an up-regulation of diglycerides and a down-regulation of triglycerides 
358 was observed. These findings point to the relevance of these lipids in this disorder and 
359 the significance of lipid trait characterization as a diagnostic tool. Targeted lipidomics 
360 analyses have also demonstrated that the lipid peroxidation marker 8-iso-prostaglandin 
361 F2α is increased in CSF from MS patients [154]. In addition, an increased incidence of 
362 CSF protein lipoxidation from MS patients has been reported as a result of augmented 
363 free radical production. Further investigations with larger sample sizes, prospective 
364 study design and with the presence of a healthy-control group are required to further 
365 elucidate the significance of such results. 
366 2.4 Parkinson’s disease
367 It has been an ongoing challenge identifying metabolic measures of disease progression 
368 in Parkinson’s disease (PD). Early biomarker investigations into PD progression have 
369 mainly focused on examining compounds of dopaminergic catabolism. Previous studies 
370 analyzed CSF homovanillate concentrations with inconsistent results [155]. A LC/MS 
371 metabolomics approach revealed a significant reduction of uric acid in PD patient 
372 plasma samples compared to controls; while an increase in glutathione was observed in 
373 response to oxidative damage [156]. Considering the well-known involvement of 
374 mitochondria [157] and the Autophagy-Lysosomal Pathway and the Ubiquitin-
375 Proteasome System [158], LeWitt and colleagues combined analysis of CSF and 
376 plasma metabolites in an effort to discover metabolomics markers of oxidative stress 
377 related to disease progression [159]. Four metabolites of purine metabolism were 
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378 among the compounds found to be biomarkers of PD progression: theobromine, 
379 theophylline, paraxanthine, and 1-methylxanthine. Caffeine intake, which is also 
380 inversely associated with the risk of developing PD [160], and the depletion of striatal 
381 dopamine might influence purine metabolism, thus explaining such a result [161]. The 
382 authors also found variations in medium and long-chain fatty acids (5-dodecanoate, 3-
383 hydroxydecanoate, docosadienoate, and Preclinical models of rotenone-treated rats had 
384 previously revealed similar changes in systemic fatty acid metabolism in rats [162,163]. 
385 In a recent study, Fagotti and colleagues demonstrated in a rotenone-rat model, 
386 undergoing chronic sleep restriction, an increase in BAACs, tryptophan, phenylalanine, 
387 and lipoproteins [163]. Others have described marked variations of PCs and LysoPCs 
388 in 6-hydroxydopamine-treated rats [164]. 
389 2.5 Huntington’s disease
390 Considering the growing evidence of impaired circadian rhythms in Huntington’s 
391 disease (HD) animal models, Morton and colleagues investigated alterations in 
392 melatonin and cortisol levels in pre-symptomatic transgenic HD sheep [165]. The 
393 authors found normal concentrations of serotonin and cortisol, whereas levels of plasma 
394 melatonin were significantly elevated, thus suggesting a compensatory neuroprotective 
395 response of melatonin in the first stages of the disorder. A number of studies have 
396 reported raised levels of citrulline in both pre-clinical and clinical models of HD, 
397 suggesting a dysfunction in the urea and NO cycles [166-168]. The possible 
398 dysregulation of CCAAT-enhancer-binding proteins (C/EBP) due to mutant huntingtin 
399 has been proposed as a causative mechanism of argininosuccinic acid synthetase and 
400 argininosuccinase acid lyase suppression [166]. 
401 2.6 Migraine
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402 Migraine is an episodic brain disorder ranking as the second most disabling disease 
403 worldwide. Suggestions of metabolic involvement in the pathogenesis of the disorder 
404 were proposed for the first time in 1935 [169], when hypoglycemic status was proposed 
405 as being responsible for the attack, and later in 1982 [170] as the role of hypoxic state 
406 and energy deficit was again raised. Unbalanced cerebral energy metabolism and/or 
407 oxidative stress due to fasting, exercise [171,172], dehydration, hypoxia [173,174] and 
408 lack of sleep [175] might indeed trigger or worsen the attack. 
409 Functional MRI studies have demonstrated that brain ATP decreases by 16% between 
410 attacks in patients with migraine without aura differently from healthy controls [176]. 
411 This finding suggested that mitochondrial oxidative phosphorylation is impaired in the 
412 brain of patients with migraine during [177] and between migraine attacks [178-184]. 
413 Mitochondrial dysfunction in migraine attacks has also been shown by increased levels 
414 of ADP and decreased levels of organophoshates. Measurement of lactate has produced 
415 mixed results [185,186]. Intriguingly, patients with migraine with aura presented 
416 elevated levels of brain lactate, but not in those with migraine without aura [187-190]. 
417 It should be considered that stimulus-induced surges in cortical lactate are physiological 
418 [191], since lactate is normally provided by astrocytes to neurons as energy provision. 
419 Accordingly, the absence of a stimulus-induced increase in lactate levels in patients 
420 with migraine could be considered pathological [192]. Indeed, the metabolic 
421 abnormalities observed during a migraine attack might reflect counter-regulatory 
422 effects rather than pathogenic alterations [192]. 
423
424 3. Metabolomics in peripheral neuropathies
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425 Peripheral neuropathies consist of a heterogeneous group of disorders characterized by 
426 peripheral nerve damage. A wide array of causes, ranging from metabolic and toxic to 
427 genetic, can be identified. Despite this apparent variety of etiologies, mitochondrial 
428 dysfunction seems to underlie the different types. In fact, a number of mutations related 
429 to mitochondrial activity have been demonstrated to be responsible for several forms of 
430 inherited neuropathies [193]. Over 80 causative genes [194,195] involved in myelin 
431 structure, axonal transport, cytoskeletal architecture, endosomal vesicular transport, 
432 and microtubule interaction have been identified [196]. Genetic testing has so far been 
433 based on algorithms, mainly related to the clinical phenotype and electrophysiological 
434 features [197]. Nevertheless, identification of a genetic profile assessing patients at high 
435 risk of peripheral neuropathy still represents an open challenge [198]. A recent study 
436 attempted to identify metabolite profiles of Charcot-Marie-Tooth-2D (CMT2D) on a 
437 GarsNmf249/+ murine model [199]. The authors found a decrease in ascorbic acid and 
438 carnitine in the spinal cord and sciatic nerve, whereas glycine showed only a modest 
439 increase. Nevertheless, differences in serum ascorbic acid levels did not correlate with 
440 the decreased ascorbate in the spinal cord. Considering the variation in carnitine levels, 
441 a dysfunction in the transport of fatty acids into the mitochondria was then hypothesized 
442 [200]. Changes in the glycine levels were instead interpreted as impaired synaptic 
443 transmission. However, Bais and colleagues stressed the need for further investigations 
444 concerning the potential role of such metabolites as markers of nerve damage in the 
445 genetic forms of neuropathy [199]. 
446 Metabolic profiling of diabetic neuropathy, which represents the most prevalent form 
447 of peripheral nerve disease, has also been investigated. Rojas and collaborators 
448 examined alterations in the metabolic pathways of DRG and peripheral nerves in a 
449 streptozotocin (STZ)-induced type 1 diabetic murine model [201]. The experiment 
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450 showed a trend for an early reduction of TCA metabolites, which became more evident 
451 in the later stage when sensory loss and nerve damage were clearly present. BCAA 
452 levels, namely valine (Val), isoleucine (Ile) and leucine (Leu), showed an increase, 
453 indicating a switch towards alternative energetic pathways. In addition, they observed 
454 a progressive rise in the levels of sorbitol with the advancing diabetic state, again 
455 suggesting a shift to a minor energetic route. The authors also reported an early 
456 inhibition of glycolytic enzymes in response to the hyperglycemic status. These 
457 progressive changes in energy utilization eventually resulting in tissue-specific 
458 dysfunction. Similarly, Freeman and colleagues investigated metabolic alterations in 
459 STZ-diabetic rats [23]. Interestingly, they found altered lipid metabolism in the distal 
460 sural nerve with an initial sparing of the DRG or the trigeminal nerve, confirming a 
461 specific distal-proximal pathogenesis in diabetic neuropathy. The different tissue 
462 composition might explain such observation. In particular, compared to the DRG and 
463 trigeminal nerve, which are essentially neuronal, in the sural nerve there is a high 
464 proportion of Schwann cells whose disruption can cause axonal 
465 degeneration/neuropathy. Despite presenting a less significant phenotypic change, the 
466 lack of support from the DRG was proposed to contribute to the axonal degeneration. 
467 Metabolomics studies have also been used to investigate metabolic profiles and patho-
468 mechanisms of myelin disruption in inflammatory neuropathies. A recent 
469 metabolomics approach based on blood analysis proposed disordered lipid metabolism 
470 as an indicator for Guillain-Barre syndrome (GBS) and its subtypes [202]. In 2018, 
471 Park and colleagues examined potential CSF biochemical linkage associated with the 
472 pathology of three GBS, including acute inflammatory demyelinating polyneuropathy 
473 (AIDP), acute motor axonal neuropathy (AMAN), and Miller Fisher syndrome (MFS) 
474 [203]. Patients with GBS exhibited reduced conductance related to demyelination 
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475 combined or not with axonal damage, which coupled with membrane lipid compounds. 
476 The CSF analysis of AMAN revealed significantly higher levels of SMs, suggestive of 
477 myelin damage [204], compared to the AIDP and MFS groups. In all three subtypes 
478 they observed elevated monoacylglycerols (1-monopalmitin and 1-monostearin) 
479 [203,205] and reduced levels of acetate, suggestive of an abnormality in myelin lipid 
480 biosynthesis [203,206-208]. CSF glucose was present at considerably higher levels in 
481 the MFS group [203]. Moreover, the significantly lower levels of acetoacetate, 
482 creatinine [202,209,210], and pyruvate [186], additionally supported the 
483 hypermetabolic status in MFS [203]. Proteinogenic amino acids were instead reduced 
484 [203]. Compared to MFS, AIDP and AMAN presented increased fatty acids, suggesting 
485 either reduced myelin lipid biosynthesis or critical demyelination process [203]. The 
486 AIDP group was further characterized by the highest levels of lysoPCs, which have 
487 been proposed as strong macrophage activation agents [211]. 
488 Chemotherapy-induced peripheral neuropathy (CIPN) is a common drug-related 
489 adverse effect of anti-neoplastic treatment [212]. Despite the fact that a clear 
490 mechanism has yet to be defined, mitochondrial dysfunction [213-216], intraepidermal 
491 nerve fiber damage [215], dysfunctional ion channels [217-219], inflammatory and 
492 immune status [220-222] seems to contribute to the pathogenesis of nerve damage. Wu 
493 and colleagues investigated metabolomics changes in patients treated with paclitaxel-
494 induced CIPN [223]. The ultra-performance liquid chromatography-electrospray 
495 ionization-mass spectrometer (UPLC-ESI-MS) analysis revealed a decrease of ePCs 
496 and lysoPCs, indoxyl sulfate, suprofen S-oxide, and 4-ethylphenylsulfate. Metabolism 
497 of fatty acids, which contributes to the biosynthesis of prostaglandins and cell 
498 membranes, and glycerophospholipids, which provide stability, permeability and 
499 fluidity to cell membranes, was primarily affected by paclitaxel. These findings support 
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500 other previous studies reporting alterations in lipids (LysoPCs or PCs), organic acids 
501 and ketones in paclitaxel-related CIPN [224-226].
502
503 4. Conclusion
504 The use of metabolomics to study biological phenotyping of neurological disorders 
505 might indeed be the key for early recognition of dysfunctional regulation, that would 
506 also imply the need for a prompt and precise intervention tailored on a patient’s profile. 
507 Despite providing a comprehensive outline of thousands of metabolites, metabolomics 
508 analysis would further require correct data interpretation for a clear understanding of 
509 the involved networks, as potential drug targets. 
510 In the last five decades, research on cancer has uncovered metabolic alterations of 
511 specific pathways in tumor cells determining their survival in stressful conditions and 
512 elevated proliferation. Reprogrammed metabolism in malignant cells determines the 
513 development and persistence of altered bioenergetics, augmented biosynthesis, and 
514 redox imbalance. Therefore, research has focused on the characterization of 
515 reprogrammed activities to determine tumor behavior, and limit tumor evolution.  
516 Glycolysis is considered a physiological response to reduced oxygen availability. In 
517 cancer, the increase in glycolytic flux and derived metabolites support the enhanced 
518 metabolic demands through ancillary pathways [227]. Besides pyruvate from 
519 glycolysis, fatty acids and amino acid oxidation can provide substrates to the TCA cycle 
520 to maintain mitochondrial ATP production in malignant cells [228]. Lipid uptake is also 
521 important during conditions of metabolic stress, and hypoxia causes a state of 
522 dependence on desaturated fatty acids in support of protein biosynthesis [229].
523 Despite the relevant genetic and pathophysiological heterogeneity of neurological 
524 disorders, current studies seem to support a similar general induction of supplementary 
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525 pathways with a different involvement according to the disease stage. Experimental 
526 models on metabolic reprogramming might be highly informative about the molecular 
527 mechanisms underlying aberrant signalling and altered metabolic fluxes. This might be 
528 relevant in terms of identification of a therapeutic window for specific clinical 
529 opportunities. It will then be critical to determine which pathways are likely to be 
530 involved for a viable therapeutic intervention.
531
532 5. Expert opinion
533 Traditional metabolomics consider the organism as a metabolic stable system and 
534 generally relies on samples taken only at one time point. Nevertheless, metabolism is a 
535 dynamic process that changes across the 24 h day to optimize energy utilization and 
536 storage in synchrony with the feeding/fasting and sleep/wake cycles. Over 50% of 
537 plasma metabolites exhibit diurnal 24 h rhythms in entrained normal living conditions 
538 [36,37]. The endogenous circadian timing system regulates some of these plasma 
539 metabolite and lipid rhythms [38-40]. In the mouse liver over 50% of metabolites have 
540 circadian rhythms [230]. It is thus challenging to define the true alteration of metabolic 
541 pathways merely by upregulation or down-regulation of metabolites without 
542 considering the dynamic changes in metabolism across the day. Most diurnal/circadian 
543 metabolomics studies, however, have so far overlooked the importance of subcellular 
544 localization of metabolites (i.e., mitochondrial vs. cytosolic pools). 
545 Further considerations, for example, mapping of many identified metabolites to specific 
546 metabolic pathways is still an open issue, since biological knowledge has not kept up 
547 with the increased progress of detection. Many metabolites currently lack biological 
548 significance, although circadian metabolomics studies may help to provide a context 
549 from which to predict their metabolic pathways. Accordingly, the extent of the 
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550 “targeted” metabolome is likely to significantly increase as more metabolite identities 
551 and related pathways are recognized.
552 The limitations inherent to the published studies need to be acknowledged, namely 
553 sample size concerns, and generalizability beyond the study’s geographic 
554 region/cohort. It is also difficult to discern whether the observed biomarkers represent 
555 primary biochemical manifestations of disease progression or downstream changes of 
556 the disorder. It should also be pointed out that the source of the measured metabolites 
557 is often not known and could also derive from the diet and gut flora. 
558 Standardized analytical methods and selection of an adequate sample size are therefore 
559 fundamental for reducing some of the potential artifacts. For example, there could be a 
560 confounding effect due to the influence of cholesterol lowering medication, which 
561 could give the appearance of lower lipid levels. In addition, the longitudinal effects of 
562 aging should be investigated for a correct interpretation of study results in pathological 
563 conditions. Considering that different panels of metabolites might produce different 
564 outcomes, the definition of a uniform analytical method targeting specific metabolic 
565 profiles might help to guarantee the repeatability and reproducibility of study results in 
566 neurological disorders.
567 Over the last 20 years, metabolomics technology has significantly advanced. Future 
568 development should focus on improving qualitative and quantitative accuracy and 
569 automatic data processing. To date, many biomarkers and differential metabolites have 
570 been found by metabolomics studies, but often with conflicting results. It is also likely 
571 that the imprecise phenotyping/classification of the neurological diseases and their 
572 subtypes, the mixed cohorts of patients (age, sex, medication) with uncontrolled 
573 sampling conditions (no control of feeding; time of day etc) has, to date, prevented the 
574 identification of clear metabolic profiles and pathways. The functional interpretation of 
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575 metabolic biomarkers in relation to cell and subcell biology could indeed play an 
576 important role in clarifying neurological disease mechanisms and disease progression.
577
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